On HRT (T-HRT or E2-HRT)
Already on hormone replacement (testosterone or estrogen) and considering layering peptides on top. Coordination with your prescriber is the precondition.
What changes during this transition
HRT-context is not a transition — it's an ongoing status that changes how peptide stacking decisions get made. The recurring question across this axis: "my HRT is dialed in; what peptides layer on top safely?" Two distinct clinical conversations: T-HRT (testosterone replacement; tracked via T + free T + SHBG + estradiol + hematocrit) and E2-HRT (estradiol replacement; tracked per the menopausal HRT or gender-affirming protocol). GH-axis peptides (CJC-1295, ipamorelin, tesamorelin) are mechanically compatible with both HRT contexts — no direct hormonal interaction — but the layered IGF-1 + metabolic monitoring matters and the prescriber needs to know. PT-141 acts independently of sex-steroid levels — useful when libido/arousal issues persist despite well-optimized HRT. Kisspeptin has a hard mechanical complication on the T-HRT side — it stimulates LH upstream while exogenous T suppresses LH downstream (community 'natural T booster' framing is mostly pharmacologically futile during TRT); its legitimate role is TRT-RESTART protocols (endocrinology-managed). Tesamorelin's clamp data showing visceral-fat reduction without worsening insulin sensitivity is the GH-axis peptide most-defensible to layer.
Important caveat
Tell your HRT prescriber BEFORE adding any peptide — not after. They're already monitoring sex-steroid + metabolic markers and need to interpret changes against your hormonal panel as a whole. Don't self-adjust your HRT dose to compensate for peptide effects (energy, body comp, sleep quality). GH-axis peptides worsen insulin sensitivity — chronic stacking on existing metabolic shifts deserves quarterly fasting glucose + HbA1c. Target mid-range IGF-1, NOT upper-quartile — the community 'optimize IGF-1' framing doubles down on a pathway HRT may already engage.
Peptides editorially relevant to on hrt (t-hrt or e2-hrt)
5 peptides from the library — each evidence-tiered honestly.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- IpamorelinTier 3
GHRP / ghrelin mimetic
Selective GH-releasing peptide with minimal cortisol or prolactin elevation in early studies. Human outcome evidence is limited.
- TesamorelinTier 1
GHRH analog
FDA-approved for HIV-associated lipodystrophy. Off-label use for general fat loss is meaningfully less supported.
- PT-141 (Bremelanotide)Tier 1
Melanocortin receptor agonist
FDA-approved as Vyleesi for premenopausal HSDD. Off-label use for male erectile function and on-demand libido is widespread but supported by far thinner evidence.
- KisspeptinTier 2
KISS1R agonist (hypothalamic neuropeptide)
Sits at the very top of the reproductive axis — triggers the cascade that produces sex hormones. Strong clinical-research evidence for hypogonadism and IVF use; off-label 'natural T' community use in healthy men runs ahead of the data.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.